Ultragenyx Pharmaceutical Inc.
Edit

Ultragenyx Pharmaceutical Inc.

https://www.ultragenyx.com/
Last activity: 24.08.2026
Active
Categories: BioTechCareFutureHealthTechLearnMarketMedtechMovingProductScience
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.

Our commitment and care for patients extends to our people, so culture is an essential cornerstone for Ultragenyx. We remain continuously focused on creating a supportive and inclusive environment of profound learning and growth – so employees can thrive in all areas of their lives, in and outside of work. Ultimately, we want to be an organization where we would be proud for our family, friends and children to work.

If you want to have a meaningful impact, do the best work of your career, and grow a lot, both professionally and personally, come join our team. During the COVID-19 Outbreak, we are committed to our hiring process. The health and safety of our employees and prospective employees take priority which means at this time our approach will include video discussions, interviews, and onboarding.
Followers
43.21K
Website visits
63.5K /mo.
Mentions
49
Location: United States, California, Novato
Employees: 501-1000
Total raised: $45M
Founded date: 2010

Investors 5

Funding Rounds 1

DateSeriesAmountInvestors
20.06.2011Series A$45M-

Mentions in press and media 49

DateTitleDescription
24.08.2026Glycogen Storage Disease Gene Therapy Approved: Cornstarch Data, Not Hypoglycemia ProofBy Otis D. Sheehan Published: Aug 24 2026, 2:50 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
02.07.2026ACD ENTERS AGREEMENT WITH ULTRAGENYX TO INVEST IN CLINICAL DEVELOPMENT OF THERAPY FOR CREATINE TRANSPORTER DEFICIENCYACD commits $4 million investment with Ultragenyx to accelerate path to treatment for CTD patients Our partnership with ACD represents a shared commitment toward a new future for CTD and addresses the urgency that treatments are needed now....
07.05.2026Rare disease families find roadmap to drug development at bootcampsRare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx’s Rare Bootcamp gives advocates a roadmap for navigating drug development. The program has helped connect families with resear...
26.02.2026Novartis settles with Henrietta Lacks’ estate over use of her ‘stolen’ cells to advance medicineGetting your Trinity Audio player ready... By BRIAN WITTE Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her kno...
29.12.2025Stocks making the biggest moves midday: Nvidia, Ultragenyx Pharmaceutical, Newmont, DigitalBridge & more-
28.12.2025S&P 500 closes lower Monday as investors sell tech names into year-end: Live updatesStocks fell on Monday, spurred by losses in technology, after the S&P 500 scaled to record levels last week. The S&P 500 dropped 0.35% and closed at 6,905.74, while the Nasdaq Composite shed 0.50% and settled at 23,474.35. The Dow J...
31.03.2025Epicrispr Biotechnologies: A New Dawn in Genetic TherapyEpicrispr Biotechnologies is making waves in the biotechnology sector. The company recently secured $68 million in Series B funding. This financial boost is a beacon of hope for patients suffering from facioscapulohumeral muscular dystrophy...
26.03.2025Epicrispr Biotechnologies Raises $68M in Series B FundingEpicrispr Biotechnologies, a South San Francisco, CA-based biotechnology company focused on developing curative therapies, raised $68m in the first close of its Series B financing. The round was led by Ally Bridge Group, with participation ...
12.09.2024The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and ActionX-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li...
10.09.2024New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)Findings from XLH Disease Monitoring Program (DMP) published in Journal of Bone and Mineral Research (JBMR Plus) DMP is a global effort, supported by Kyowa Kirin, to advance understanding and care of XLH through real-world research Addition...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In